Preimplantation Genetic Testing (PGS/PGD) Market

The global preimplantation genetic testing (PGS/PGD) market size is projected to expand at a significant CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the wide adoption of the in-vitro fertilization (IVF) procedure and the rapid use of preimplantation genetic diagnosis (PGD). These methods are beneficial in various ways that they allow the development of a healthy fetus while avoiding the possibility of selective pregnancy termination.

Get Free Sample Report

Wide adoption of preimplantation testing and screening processes can be primarily due to an increase in the occurrence of single gene, mitochondrial, and other gene-related disorders among a large number of population worldwide. According to the Florida Department of Health, about one out of every 28 babies in the state is diagnosed with a birth defect each year. For a healthy pregnancy, the PGD is used prior to decision for IVF. However, PGD is widely used in IVF procedures for women who have had multiple miscarriages or who have had a previous pregnancy with a chromosome abnormality. Early identification of congenital diseases in the early stages of the IVF workflow reduces the risk of hereditary chromosomal anomalies in the fetus over time. This present a key aspect of the market development.

PGD has the potential to support couples at risk of genetic disorders and the idea of aneuploidy screening during PGD is likely to improve IVF treatments. The implementation of aneuploidy testing in IVF clinics has resulted in a higher rate of successful pregnancy. A research study published in the journal Fertility and Sterility in August 2018 stated that the chance of good IVF pregnancy outcomes was higher using Natera's Spectrum PGT for aneuploidy (PGT-A).

Market Trends, Drivers, Restraints, and Opportunities

• Increasing occurrence of genetic disorder after the birth and wide prevalence of other gene-related disorders during pregnancy are expected to boost market growth.
• Advancement in innovative technology for genetic diagnosis such as the introduction of PGT monogenic disease diagnosis (PGT-M) is expected to spur the market development.
• Rising number of favorable government policies to promote awareness campaign about several pregnancy-related disorder and increasing development for healthy reproductive process are driving the market expansion. For example, the Swiss government approved the pre-implantation genetic diagnosis of an in-vitro embryo in June 2017.
• Social dogma and legal complexities associated with the identifying and mitigating genetic abnormalities in embryos prior to implantation are key challenges that can hamper the market growth.
• Growing understanding of fetus health among married couples as well as expanding applications of PGD and preimplantation genetic screening (PGS) are projected to boost market growth.

Scope of the Report

The report on the global preimplantation genetic testing (PGS/PGD) market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

PGD segment is expected to hold a dominant market share

Based on techniques, the global preimplantation genetic testing (PGS/PGD) market is bifurcated into PGS and PGD. The PGD segment is expected to hold a dominant market share in the coming years owing to increase knowledge among healthcare professionals and consumers about genetic testing of a particular gene mutation. Moreover, the segment growth is attributed to the rising occurrence of single gene diseases and translocation event, as well as market entities' successful delivery of NGS technology for genetic testing.

The PGS segment, on the other hand, is projected to account for a large market share in the coming years owing to wide adoption of the technique as it allows the detection of chromosomal defects in embryos. These PGS services are normally recommended by doctors for couples who are past reproductive age and have undergone multiple IVF cycles and also experienced recurrent pregnancy loss. Furthermore, increasing demand and the effective evolution of IVF procedures due to increasing pregnancy disorders and establishment of better facilities are pushing the segment growth. Moreover, a large number of IVF processes are performed in high-capacity laboratories, which improve the quality of PGS services and development.

Aneuploidy screening segment is projected to register a high CAGR

On the basis of types, the market is divided into embryo testing, aneuploidy screening, chromosomal abnormalities, X-linked diseases, HLA typing, and other PGT types. The embryo testing segment is further classified as fresh embryo (own eggs), frozen embryo (own eggs), fresh embryo (donor eggs), and frozen embryo (donor eggs). In terms of revenue generation, the embryo testing segment held a major share of the market in 2018 due to wide PGT implementation for detecting chromosomal anomalies. However, the aneuploidy screening segment is projected to register a high CAGR during the forecast period owing to the constant production of aneuploidy detection techniques, which is very common in advanced maternal age. During the forecast period, the HLA typing segment is expected to grow at a significant rate due to the high success rate of hematopoietic reconstitution in babies due to stem cell transplantation obtained from HLA-matched offspring.

HLA typing for stem cell therapy segment to exhibit rapid growth

Based on applications, the global preimplantation genetic testing (PGS/PGD) market is divided into embryo HLA typing for stem cell therapy, IVF prognosis, late onset genetic disorders, inherited genetic disease, and others. The HLA typing for stem cell therapy segment to exhibit rapid growth owing to wide demand for preimplantation genetic testing in embryo HLA typing for stem cell therapy. This is because, as opposed to unrelated donors, hematopoietic stem cell transplantation from associated matched donors results in a higher survival rate. The growing number of inherited genetic diseases in offspring, such as cystic fibrosis, hemoglobin disorders, as well as the transmission of these diseases to future generations are likely to boost the segment growth.

Get Free Sample Report

Asia Pacific is a fast-growing market

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe led the preimplantation genetic testing market in terms of revenue share in 2020 owing to a higher acceptance of IVF procedures due to a large number of late pregnancies cases. Furthermore, the market growth is bolstered by liberal aneuploidy screening legislation.

On the other hand, Asia Pacific is expected to register a high CAGR during the forecast period. the regional market growth is attributed to the introduction of a number of supporting government legislations by emerging nations such as China and India towards reproductive health developments. The presence of regulatory bodies such as the Japanese Society of Obstetrics and Gynecology (JSOG), which approves and monitors the challenges associated with reproductive health in Japan present another key aspect for the market growth in the region. Furthermore, increased IVF procedure utilization translates to high PGT workflow adoption, which is expected to accelerate the market growth in Asia Pacific.

Get Free Sample Report

Segments

Segments Covered in the Report
The global preimplantation genetic testing (PGS/PGD) market has been segmented on the basis of

Techniques

• PGS
• PGD

Types

• Embryo Testing
  • Fresh Embryo (Own Eggs)
  • Frozen Embryo (Own Eggs)
  • Fresh Embryo (Donor Eggs)
  • Frozen Embryo (Donor Eggs)
• Aneuploidy Screening
• Chromosomal Abnormalities
• X-Linked Diseases
• HLA Typing
• Other PGT Types

Application

• Embryo HLA Typing For Stem Cell Therapy
• IVF Prognosis
• Late Onset Genetic Disorders
• Inherited Genetic Disease
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Illumina Inc.
• Thermo Fisher Scientific, Inc.
• Natera, Inc.
• Bioarray S.L.; Good Start Genetics, Inc.
• Laboratory Corporation of America Holdings.
• California Pacific Medical Center;
• Quest Diagnostics Incorporated.
• Reproductive Health Science Ltd.
• CooperSurgical, Inc.
• Genea Limited.
• IGENOMIX.
• Reproductive Genetic Innovations, LLC.
• F. Hoffmann-La Roche AG
• Combi Matrix

Competitive Landscape

Some of the key players operating in the market are Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, LLC; F. Hoffmann-La Roche AG; and CombiMatrix. The market share of key players in genetic diagnosis that integrate continuous advances for effective implementation of PGT and screening have increased significantly. Several strategic steps are taken by key players including regional extensions, joint developments, and new product growth.